Medidata Acorn AI’s commercial data management technology helps identify previously untreated and undiagnosed patients
Medidata, a Dassault Systèmes company, the global leader in creating end-to-end solutions supporting the entire clinical trial process, announced that its Acorn AI commercial data management technology was used by oncology biopharmaceutical company EUSA Pharma for the U.S. commercial relaunch of SYLVANT (siltuximab).
Medidata Acorn AI Commercial Data Solutions provides commercial pharmaceutical organizations with the data management and insights needed to maximize brand success. EUSA Pharma is using Medidata’s STRATA end-to-end commercial data management platform and LUMEN Insights to empower its sales and marketing teams with data-driven insights to identify previously untreated patients, remove barriers to treatment, and improve patient adherence.
Recommended AI News: Side Becomes A Unicorn Company Following $150 Million Series D Financing
“We consider Medidata Acorn AI technology to be the cornerstone of our digital commercial analytics platform. This helped us maintain a lean infrastructure, and more importantly better understand our business,” said Mickey Baker, Head of U.S. Market Access & Operations at EUSA Pharma. “Medidata Acorn AI Commercial Data Solutions worked as a trusted extension of our team, not only from a technological viewpoint, but for their data expertise as well.”
The commercial data model developed through the Medidata Acorn AI Commercial Data Solutions team is designed to scale with new indications and products, which will complement EUSA Pharma’s planned commercial strategy and operations. The commercial data model will enable people at all levels of EUSA Pharma to access a single source of truth and create readable, intuitive reports about SYLVANT’s commercial performance.
Recommended AI News: Bruin Sports Capital Reaches Agreement with Quadrant Private Equity To Become Co-Owner of Global Sports Technology Company: TGI Sport
“Our Commercial Data Solutions team completed a fully remote implementation of STRATA and LUMEN to support EUSA Pharma’s SYLVANT relaunch,” said Frank Lane, Medidata Acorn AI, vice president, Customer Success and Delivery Excellence. “It speaks to our team’s technical expertise and ability to be nimble and adjust during the COVID-19 pandemic, as we continue to help pharmaceutical companies execute on their launch strategies.”
From identifying and retaining patients, discovering biomarkers, accelerating diagnosis, and delivering insights into complex patient populations, Medidata is advancing oncology and rare disease trials by expediting outcomes and improving experiences. These diseases are often poorly understood with limited treatment options and data for physicians to select the most appropriate therapy for patients. For example, Medidata published research, in collaboration with the Castleman Disease Collaborative Network, which used Rave Omics to identify potential biomarkers for early response to treatment.
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
Recommended AI News: Neudata Launches Alt Data Legal and Compliance Intelligence Tool Neudata Sentry
Comments are closed.